HRS 2020: Boston Scientific’s Next-Gen LAAC Device Hits Targets In PINNACLE FLX Trial
Executive Summary
The PINNACLE FLX trial of the next-generation WATCHMAN left atrial appendage closure device met its primary safety and effectiveness endpoints with a low adverse event rate of 0.5%.
You may also be interested in...
Conformal Medical Raises $85M To Advance Its Left Atrial Appendage Closure Device
The series C financing will support development of its CLAAS device, an alternative to anticoagulant drugs for atrial fibrillation patients.
Boston Scientific Remains On Track For Return To Growth By 2021
The company’s sales declined 29% in the second quarter of 2020 due to the pandemic, but sales trends indicate the start of a worldwide recovery across all of Boston Scientific’s businesses.
Boston Scientific Expects Up To $40M Impact In Q1 From Coronavirus Outbreak; 10%-12% Revenue Increase For 2020
Boston Scientific said in an earnings call it expects the coronavirus outbreak may lead to a $10m to $40m loss in first-quarter sales as a result of lower procedures volumes and disrupted supply chains in China. For the fourth quarter, Boston Scientific reported $2.9bn in sales.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: